Pfizer said on Friday that clinical trials of its experimental coronavirus pill reduced the risk of hospitalization and death for high-risk patients.
The antiviral pill, which is combined with a low dose of an HIV drug called ritonavir, can reduce hospitalizations or deaths from Covid-19 by up to 89% in high-risk patients, Pfizer said in a report. Press release.
Pfizer said an independent panel of experts overseeing its clinical trial recommended the study be stopped early because the drug’s benefits to patients were so compelling. The company said it plans to submit the data as soon as possible to the Food and Drug Administration to seek permission to use the pill in the United States.
Albert Bourla, CEO of Pfizer, called the drug “revolutionary” in a statement. “These data suggest that our oral antiviral candidate, if approved by regulatory authorities, has the potential to save patient lives, reduce the severity of Covid-19 infections, and eliminate up to nine hospitalizations on ten “, did he declare. Pfizer said it plans to ask the Food and Drug Administration to clear the drug combination “as soon as possible.”
Pfizer, together with its European partner BioNTech, developed the first coronavirus vaccine authorized in the United States and Europe. The Pfizer pill in development is said not to be a vaccine to protect people from the virus, but a drug to treat people who catch the virus.
The company announced in late March that it was starting clinical trials of the oral drug. The company said the oral drug works by blocking protease, an essential enzyme the virus needs to replicate. Protease inhibitors are used in medicines to treat HIV and hepatitis C.